Kalicit

KALİSİT  effervescent tablets
KALICIT

International non-patented name: Kalicit

Composition:
Active ingredients: 1 tablet contains 2.17 g of potassium citrate, 2.0 g of potassium bicarbonate, 2.057 g of anhydrous citric acid.
Excipients: sucrose and glucose syrup, macrogol 6000, saccharin, lemon flavoring D-Sorbitol.

Description:
They are white, round-shaped, effervescent tablets with a rough surface and sharp edges on both sides.

Pharmacotherapeutic group:
Medicine to normalize potassium balance and prevent the formation of kidney stones.

ATC: A12BA30.

Pharmacological properties:

Pharmacodynamics
Calcite reduces the concentration of potassium salts and prevents crystallization in urine. It alkalinizes the urine by raising its pH. Due to this alkalizing effect, it also increases the dissociation of uric acid and reduces the formation of urate salts.

Potassium citrate is superior to sodium citrate in preventing urolithiasis. Citrate affects the physico-chemical composition of urine: it increases the solubility of urates, reduces the calcification of oxalate, helps to dissolve formed stones.

Pharmacokinetics
Most of the ingested potassium-citrate is absorbed and completely oxidized to carbon dioxide and water. Excess alkaline cations formed during this period are excreted by the kidneys within 24-48 hours without changing the acid-alkaline balance of the blood. Most of the ingested potassium-citrate is absorbed and completely oxidized. At this time, potassium ions are released. During hypokalemia, potassium ions increase the urinary excretion of citrater.

Instructions for use:
In the case of potassium deficiency in the human body:

• severe hypokalemia (